Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer.
Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer.
复制标题
血浆 miRNA-30a 增加作为非小细胞肺癌的生物标志物
DOI：
10.12659/msm.897330
复制
发表时间：
2016-02-26
期刊：
影响因子：
--
通讯作者：
Luo F
中科院分区：
文献类型：
--
作者：
Sun L;Chen Y;Su Q;Tang X;Liang Y;Che G;Luo F
MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. This study was conducted to investigate the expression of miRNA-30a in plasma of patients with non-small cell lung cancer (NSCLC). The plasma miRNA-30a in 87 patients with NSCLC, 20 patients with benign lung diseases, and 76 healthy subjects were measured by real-time PCR. The diagnostic value of miRNA-30a in NSCLC was evaluated via the ROC curve method. Plasma miRNA-30a level was significantly higher in the NSCLC group compared with benign control and healthy control groups (P<0.01). No statistically significant difference was found in the expression level of miRNA-30a among various clinical pathologic features in NSCLC. ROC curve analysis showed that the specificity and sensitivity cut-off points were at 61.0% and 84.3% for NSCLC. The specificity and sensitivity values were 54.9% and 94.4%, respectively, in the analysis based on in-patients only. All these results suggest that plasma miRNA-30a measurement may be a novel and noninvasive method for NSCLC preliminary screening and differential diagnosis.
